Detection of serum β2-GPI–Lp(a) complexes in patients with systemic lupus erythematosus

Chunni Zhang,Ke Li,Beilei Shi,Xiangdong Wang,Xiaozhuan Liu,Weisong Qin,Aizhong Han,Junjun Wang

DOI: https://doi.org/10.1016/j.cca.2009.12.008

IF: 6.314

2010-01-01

Clinica Chimica Acta

Abstract:Results Both Lp(a) (400 ± 213 mg/l vs . 181 ± 70 mg/l) and ox-Lp(a) (27.07 ± 22.30 mg/l vs . 8.20 ± 4.55 mg/l) concentrations were higher in SLE patients than in controls ( P < 0.0001). β 2 -GPI–Lp(a) complexes were detectable in both controls and SLE. The complexes levels in SLE were higher than in controls (0.96 ± 0.41 U/ml vs. 0.59 ± 0.20 U/ml, P < 0.0001) and was positively correlated with ox-Lp(a) ( P < 0.001). Conclusions We report the existence of β 2 -GPI–Lp(a) complexes in both controls and SLE patients. The complexes levels increase in SLE. Keywords Lipoprotein(a) Oxidative modification β 2 -glycoprotein-I Enzyme-linked immunosorbent assay Oxidative stress Atherosclerosis Risk factor 1 Introduction Systemic lupus erythematosus (SLE) is a multifactorial polysystemic autoimmune disorder and is associated with premature atherosclerosis. It has been shown that premature or accelerated atherosclerosis is an important cause of morbidity and mortality in patients with SLE [1,2] . However, traditional cardiovascular risk factors do not fully explain the excessive cardiovascular events observed in these patients [2,3] . Therefore, exploration and evaluation of new risk factors are needed to further expand our capacity to predict atherothrombotic events when these factors are included along with the traditional ones in the assessment of cardiovascular risk in SLE patients. The prothrombotic state of SLE is associated with the presence of antiphospholipid antibodies. β 2 -GPI is the major autoantigen for anticardiolipin antibodies found in the sera of SLE patients and other autoimmune diseases and is characterized by its ability to bind to negative charged molecules, including lipoproteins [4–7] . A small amount of plasma β 2 -GPI is bound to the low-density lipoprotein (LDL) molecule in circulation [8] . Recently, it was shown that β 2 -GPI specifically interacted with oxidized LDL (ox-LDL), a principal lipoprotein contributing to the development of atherosclerosis, and formed complexes with ox-LDL in the intima of atherosclerotic lesions and the complexes were taken up avidly by macrophages via anti-β 2 -GPI autoantibody-mediated phagocytosis [9] . More recently, it has been demonstrated that these complexes can be found in the bloodstream of patients with autoimmune, such as SLE and antiphospholipid syndrome [10–14] . These results indicate that serum β 2 -GPI–ox-LDL complexes contribute to the development of autoimmune-mediated atherosclerosis in SLE [9–14] . Lipoprotein(a) [Lp(a)] is a key molecule in the fibrinolytic and atherogenic systems that structurally resembles LDL particle but contains a molecule of apolipoprotein(a) [apo(a)] attached to apoB-100 by a disulfide bond [15] . Elevated plasma concentrations of Lp(a) have been shown to be one of the independent risk factor for premature atherosclerosis in SLE and other diseases [16–19] . In vitro studies demonstrated that β 2 -GPI bound with high affinity to Lp(a) [20,21] , suggesting that β 2 -GPI might bind to Lp(a) to form complexes in vivo . Therefore, in this study, we developed an enzyme-linked immunosorbent assay (ELISA) for measuring serum β 2 -GPI–Lp(a) to make sure the existence of the complexes in circulation, and to investigate their value as a risk factor for the development of premature atherosclerosis in SLE. 2 Materials and methods 2.1 Subjects and blood collection Forty-seven consecutive patients with an average age of 31.8 ± 10.7 y (male 9, female 38) were randomly selected from the Nephrology Department, Jinling Hospital. All patients fulfilled ≥ 4 of the revised American College of Rheumatology criteria for the classification of SLE [22] . Forty-two healthy subjects matched for age and sex (mean age 31.0 ± 8.3 y, male 8, female 34) with no history of autoimmune, infectious or thrombotic diseases were selected for comparison. The blood was sampled at least 12 h after fasting and serum was separated immediately and stored at − 70 °C until analysis. This study was approved by the Ethics Committee of Jinling Hospital and all the subjects had given their informed consent. 2.2 Purification of β 2 -GPI and the production of polyclonal antibody against β 2 -GPI β 2 -GPI was purified from normal human plasma as described previously with slight modifications [23] . Briefly, pooled plasma from healthy donors was precipitated with perchloric acid, followed by ion-exchange chromatography on a DEAE-cellulose-52 column. β 2 -GPI was then further purified with a heparin-Sepharose 6B column. The final β 2 -GPI fraction was delipidated by extensive washing with n -butanol. The β 2 -GPI sample was checked by SDS-PAGE, Western blot and amino acid sequencing [24] . Rabbit antisera against β 2 -GPI from Millipore (CHEMICON/Upstate/Linco) were used as antibody standard. Antibodies to β 2 -GPI were obtained by immunization of New Zealand white female rabbits with purified β 2 -GPI. Both reactivity and specificity of the resulting rabbit antisera were evaluated with ELISA and Western blot. 2.3 Isolation and oxidation of Lp(a) Lp(a) was purified from plasma of healthy donors by sequential density ultracentrifugation, followed by a gel-filtration chromatography as described by Albers et al. [25] . Purified Lp(a) was diluted in phosphate-buffered saline (PBS) to a protein concentration of 0.5 mg/ml and incubated with 30 μmol/l CuSO 4 for 12 h at 37 °C, followed by extensive dialysis against 0.01 mol/l PBS with 0.1 mmol/l EDTA in pH 7.4, respectively [26] . The degree of oxidation was quantified by relative electrophoretic mobility (REM) and the generation of thiobarbituric acid-reactive substances (TBARS). 2.4 Production of polyclonal antibody against apo(a) Polyclonal antibodies to apo(a) were obtained by immunization of sheep with Lp(a), and then the cross-reactivity in these Lp(a) antisera against LDL, plasminogen and other apolipoproteins was removed by absorbing on an affinity chromatographic column of Sepharose 4B (Pharmacia) coupled with plasminogen and pooled sera obtained from Lp(a)-negative subjects as previously described [27] . The obtained polyclonal sheep anti-apo(a) reacts with both native and oxidized Lp(a), but not with plasminogen and LDL [27] . 2.5 Sandwich ELISA for β 2 -GPI–Lp(a) Five hundred microliters of serum was firstly incubated with MgCl 2 (final concentration 10 μmol/l) at 37 °C for 2 h, and then polyethyleneglycol (PEG)-6000 (Sigma) was added to isolate β 2 -GPI–Lp(a) from endogenous free form of β 2 -GPI to eliminate the possible influence of endogenous free β 2 -GPI to the assay. The samples, were incubated overnight at 4 °C and then centrifuged at 10,000 rpm for 20 min. The precipitates were resuspended in 500 μl washing solution containing 0.5% gelatin in 0.01 mol/l PBST (0.01 mol/l PBS containing 0.05% Tween-20). We developed a sandwich ELISA method to measure the complexes of β 2 -GPI with Lp(a). Microtitre plates were coated for 2 h at 37 °C and then overnight at 4 °C with 100 μl/well anti-human β 2 -GPI antibody in 0.05 mol/ml, pH 9.6, sodium carbonate/bicarbonate buffer (8 μg/ml, 100 μl). After washed three times with 0.01 mol/l PBS, the plates were quenched with 1% gelatin in 0.01 mol/l PBS for 1 h at 37 °C. One hundred microliters of diluted (1:6) serum samples (resuspended with gelatin in PBST) or serial reference sera were added to the wells and incubated for 2 h at 37 °C. After washing, 100 μl volume of HRP-labeled polyclonal antibody against apo(a) was added to each well and incubated for 2 h at 37 °C. The wells were washed and color was developed by adding 100 μl o -phenylenediamine and H 2 O 2 . After 15 min at room temperature, the enzyme reaction was stopped with 100 μl 2 mol/l sulfuric acid and the absorbance was measured at 450 nm. A pooled fresh-frozen serum sample (from 50 healthy subjects) was used as reference serum of β 2 -GPI–Lp(a). Reference serum was also precipitated every time as serum sample. The two SD above the mean optical density (OD) of our studied 42 samples from healthy blood donors was arbitrarily expressed as 1 U/ml. The value of reference serum was then assigned (0.6 U/ml). A sample was considered to be positive when its level was higher than 1.00 U/ml. 2.6 Sandwich ELISA for Lp(a) and ox-Lp(a) Lp(a) was measured by a sandwich ELISA using monoclonal anti-apo(a) as the capture antibody and detected with polyclonal anti-apo(a) enzyme conjugates as previously described [28] . Reference serum of Lp(a) was from Immuno AG Vienna. Ox-Lp(a) was measured by a sandwich ELISA using polyclonal antibody against ox-LDL as the capture antibody and detected with monoclonal anti-apo(a) enzyme conjugate as previously described [27] . Antibodies to ox-LDL were obtained by immunization of New Zealand white female rabbit with ox-LDL as described by Virella et al. [29] . The resulted rabbit antisera were first fractionated by affinity chromatography with immobilized protein G, and the IgG fractions were then absorbed in a column of immobilized native LDL. The washout from the column of immobilized native LDL, containing antibodies to ox-LDL and irrelevant IgG, was used to capture ox-LDL, which had no reactivity with native LDL [27] . Calculation of the concentration of ox-Lp(a) was based on the concentration of ox-Lp(a) as the standard [27] . 2.7 Determinations of other lipids Serum levels of total cholesterol (TC), triacyglycerols (TG) (RANDOX, England), LDL-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and apoB (Daiichi Pure Chemicals, Japan) were measured on a Hitachi 7600 analyzer. 2.8 Statistical analyses Statistical analyses were performed with SPSS 13.0. The values were expressed as mean ± SD. Comparison among the groups was performed using unpaired t test. The correlations between variables were calculated by the nonparametric Spearman Rank Coefficient test. A P < 0.05 was considered as statistically significant. 3 Results 3.1 Characterization of β 2 -GPI The purity of prepared β 2 -GPI was demonstrated by the presence of a single 50 kDa protein band identified by SDS-PAGE (as showed in Fig. 1 ). Western blot analysis showed that the purified β 2 -GPI reacted strongly with polyclonal rabbit anti-β 2 -GPI antiserum from Millipore, as well as with self-prepared antiserum and produced precipitable bands ( Fig. 2 ). 3.2 ELISA for detecting β 2 -GPI–Lp(a) Checker-board analyses were firstly performed to determine the optimal requirement for different assay components. Rabbit anti-human β 2 -GPI antiserum was used at 10 μg/ml to 0.625 μg/ml. HRP-labeled polyclonal antibody against apo(a) was used at 1:1000 to 1:16,000 dilution. Serum samples were tested with serial dilutions (from1:1 to1:32 dilutions). Three serum samples ranging from low to high concentrations with serial dilutions were precipitated with different concentrations of PEG (from 4% to 6%) to choose the better concentration of precipitant. The checker-board analyses have indicated the following optimal conditions: capturing antibody at 2.5 μg/ml concentration, quantitating antibody at 1:4000 dilution, serum at 1:6 dilution and PEG at 4.5% concentration. After determining the optimal conditions, we proceeded to analytical characterization of the ELISA assay. The linear range of the assay was 0.32–1.11 U/ml ( Fig. 3 ). For the statistical analysis of the reproducibility of the ELISA assay, we used three serum samples ranging from low to high concentrations. The mean intra-assay coefficient of variance (CV) was 6.61% (5.14–8.28%) as evaluated by assaying 12 replicates of each sample in a single assay. The mean inter-assay CV was 13.02% (9.56%–16.50%) as evaluated by 7 subsequent measurements of the tests samples. 3.3 Serum lipid and apolipoprotein concentrations in patients with SLE Serum TC, LDL-C, TG and apoB concentrations were all significantly increased, whereas HDL-C concentrations were decreased in patients with SLE. Lp(a) and ox-Lp(a) levels were also significantly higher in SLE patients than in controls ( Table 1 ). 3.4 Serum β 2 -GPI–Lp(a) concentrations in patients with SLE The serum levels of β 2 -GPI–Lp(a) complexes in SLE patients (0.96 ± 0.41 U/ml, median: 0.88 U/ml) were significantly higher as compared to controls (0.59 ± 0.20 U/ml, median: 0.54 U/ml) ( P < 0.0001) ( Fig. 4 ). Twenty lupus patients were found to have elevated β 2 -GPI–Lp(a) concentrations (sensitivity 42.6%), whereas only two out of forty-two healthy controls had positive values above cut-off (specificity 95.2%). 3.5 The relationships between β 2 -GPI–Lp(a) and other lipid traits Table 2 shows the relationships between β 2 -GPI–Lp(a) and other lipid traits in SLE patients. Elevated complexes levels in SLE were only significantly associated with ox-Lp(a) ( P < 0.001), but not with any other lipid parameter, including Lp(a). 4 Discussion In this study, we developed and optimized a novel sandwich ELISA for detecting serum concentration of β 2 -GPI–Lp(a) complexes to make sure in vivo the occurrence of the complexes of β 2 -GPI with Lp(a). Our study demonstrated for the first time the existence of complexes of β 2 -GPI with Lp(a) in human circulation. Furthermore, we found that serum β 2 -GPI–Lp(a) concentrations were significantly elevated in SLE patients as compared with healthy controls. In addition, a significantly positive correlation was found between the complexes and ox-Lp(a) levels in SLE patients. SLE is associated with premature atherosclerosis, and the increased susceptibility of plasma lipids and lipoproteins to oxidation could at least in part explain the pathogenesis [30–32] . It has been identified that elevated levels of ox-LDL together with elevated levels of autoantibodies related to ox-LDL are risk factors for cardiovascular disease in patients with SLE [31,33] . Recent studies suggest that the so-called oxidation theory of atherosclerosis' may also be applied to Lp(a) [16] . Our previous studies showed that ox-Lp(a) was detectable in human blood and its concentrations increased in patients with coronary artery disease [27] and in rheumatoid arthritis patients with excessive cardiovascular events [34] . Recently, antibodies reacting against oxidized Lp(a) by malondialdehyde have been described in SLE, which suggests the existence of ox-Lp(a) in SLE [35] . However, whether there is any difference in the level of ox-Lp(a) between SLE patients and healthy controls remains to be determined. In this study, we measured for the first time the ox-Lp(a) levels in SLE patients and found that ox-Lp(a) concentrations in the patients were markedly elevated as compared with controls ( P < 0.0001). As we know, β 2 -GPI is characterized by its ability to bind lipoproteins, prothrombin, lecithin and other negatively charged materials [4–7] . Although β 2 -GPI can bind to both native LDL and oxidized LDL, it has been shown that β 2 -GPI binds with higher affinity with ox-LDL as compared with native LDL, due to the increased negative charges on the surface of oxidized LDL particle resulting from the derivatization of lysine residues induced by lipid peroxidation of LDL [36] . As the antibody against apo(a) used in our assay can react with both native and oxidized Lp(a) [27] , the β 2 -GPI–Lp(a) complexes detected in our study should be the complexes of β 2 -GPI with both native Lp(a) and ox-Lp(a). The oxidation pattern of Lp(a) has been described as similar to that of LDL and the negative charges on the surface of oxidized Lp(a), just like that of ox-LDL, are also markedly increased as compared with corresponding native molecule [35] . Thus, we supposed that β 2 -GPI preferentially binds with ox-Lp(a) to native Lp(a). To clarify the hypothesis, in this study, we investigated the association of β 2 -GPI–Lp(a) complexes with Lp(a) and ox-Lp(a). It is noteworthy that we observed that β 2 -GPI–Lp(a) complexes levels in SLE patients exhibited significantly positive correlation with only ox-Lp(a), while not with native Lp(a). This result suggests that ox-Lp(a) was probably the preferential form associated with β 2 -GPI. However, further studies are needed to clarify this issue. Traditional risk factors can only partially explain a markedly elevated risk for coronary heart disease in SLE [2,3] . Besides the traditional risk factors, the association between SLE and atherosclerosis can be attributed to additional risk factors closely related to inflammation and autoimmunity [37] . In particular, several autoantibodies and autoantigens including β 2 -GPI have been identified as possible factors in the development and progression of the atherosclerotic process in SLE [37] . It has been observed the presence of circulating complexes of β 2 -GPI with LDL or ox-LDL and the elevated levels of β 2 -GPI–ox-LDL complexes in patients with SLE, suggesting that β 2 -GPI–ox-LDL may represent a marker of significant vascular injury and oxidative stress as well as an active role in autoimmune-mediated atherothrombosis [12,36,37] . In this study, we demonstrated that β 2 -GPI also formed complexes with Lp(a) in the blood stream of healthy subjects and patients with SLE, and the serum levels of β 2 -GPI–Lp(a) complexes in patients with SLE were significantly higher than those in controls ( P < 0.0001). This result indicates new potential roles for Lp(a) in fibrinolysis and autoimmunity. In addition, we also observed a positive association between the levels of β 2 -GPI–Lp(a) and β 2 -GPI–ox-LDL in SLE patients (data not shown). Autoimmune vascular inflammation and oxidative stress in SLE contribute to the formation of both ox-LDL and ox-Lp(a) and subsequently the formation of the complexes of β 2 -GPI with ox-LDL and ox-Lp(a). These new risk factors might act as an additional predictor of premature atherosclerosis in SLE patients. In conclusion, we developed a novel method for detecting the serum levels of β 2 -GPI–Lp(a) complexes and found that β 2 -GPI–Lp(a) complexes were present in both normal subjects and patients with SLE. Furthermore, the complexes concentrations were found to be significantly elevated in SLE patients compared to controls, and to be positively correlated with the levels of ox-Lp(a) but not those of Lp(a). These results should encourage further studies of the pathogenic role of the β 2 -GPI–Lp(a) complexes and the clinical value of detecting the complexes as a risk factor for the development of atherosclerosis. Acknowledgements This work was supported by the grants from National Natural Science Foundation of China (NSFC 30872411 and 30950100 ). Appendix A Supplementary data Appendix A Supplementary data Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.cca.2009.12.008 . References [1] W.N. Huang T.K. Tso H.Y. Huang Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus Rheumatol Int 27 2007 453 458 [2] S. Zampieri L. Iaccarino A. Ghirardello Systemic lupus erythematosus, atherosclerosis, and autoantibodies Ann N Y Acad Sci 1051 2005 351 361 [3] S.L. Nuttall S. Heaton M.K. Piper U. Martin C. Gordon Cardiovascular risk in systemic lupus erythematosus—evidence of increased oxidative stress and dyslipidaemia Rheumatology (Oxford) 42 2003 758 762 [4] J. Nimpf E.M. Bevers P.H. Bomans Prothrombinase activity of human platelets is inhibited by β 2 -glycoprotein I Biophys Acta 884 1986 142 149 [5] J. George D. Harats B. Gilburd Immunolocalization of β 2 -glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression Circulation 99 1999 2227 2230 [6] E. Polz G.M. Kostner The binding of β 2 -glycoprotein I to human serum lipoprotein: distribution among density fraction FEBS Lett 102 1979 183 186 [7] I. Schousboe β 2 -glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway Blood 66 1985 1086 1091 [8] O. Vaarala Autoantibodies to modified phospholipid protein complexes markers cardiovascular diseases J Intern Med 247 2000 381 384 [9] E. Matsuura K. Kobayashi T. Koike Y. Shoenfeld M.A. Khamashtab G.R.V. Hughes Atherogenic autoantigen-oxidized LDL complexes with β 2 -glycoprotein I Immunobiology 207 2003 17 22 [10] E. Matsuura L.R. Lopez Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11 2004 103 111 [11] D. Lopez I. Garcia-Valladares C.A. Palafox-Sanchez Oxidized low-density lipoprotein/beta2- glycoprotein I complexes and autoantibodies to oxLig-1/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome Am J Clin Pathol 121 2004 426 436 [12] L.R. Lopez D.F. Simpson B.L. Hurley E. Matsuura OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement Ann N Y Acad Sci 1051 2005 313 322 [13] L.R. Lopez T.R. Buckner B.L. Hurley K. Kobayashi E. Matsuura Determination of oxidized low-density lipoproteins (ox-LDL) versus ox-LDL/beta2GPI complexes for the assessment of autoimmune-mediated atherosclerosis Ann N Y Acad Sci 1109 2007 303 310 [14] E. Matsuura K. Kobayashi B.L. Hurley L.R. Lopez Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome Lupus 15 2006 478 483 [15] A.M. Scanu Lipoprotein(a) and atherosclerosis J Intern Med 115 1991 209 218 [16] F.I. Romero M.A. Khamashta G.R. Hughes Lipoprotein(a) oxidation and autoantibodies: a new path in atherosclerosis Lupus 9 2000 206 209 [17] E. Peros D. Geroldi S. Bugatti Analysis of the apolipoprotein (a) size polymorphism in patients with systemic lupus erythematosus Int J Mol Med 15 2005 661 665 [18] R.A. Sari M.F. Polat S. Taysi E. Bakan I. Capoglu Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus Clin Rheumatol 21 2002 520 524 [19] Y.Y. Zhuang J.J. Li J.J. Wang Apolipoprotein phenotypes in cardiocerebrovascular diseases Chem Phys Lipids 67/68 1994 291 297 [20] S. Kochl F. Fresser E. Lobentanz G. Baier G. Utermann Novel interaction of apolipoprotein(a) with β 2 -glycoprotein I mediated by the kringle IV domain Blood 90 1997 1482 1489 [21] F. Lopez-Lira L. Rosales Leon V.M. Martinez B.H. Ruiz-Ordaz The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen Biochim Biophys Acta 1764 2006 815 823 [22] E.M. Tan A.S. Cohen J.F. Fries The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1982 1271 1279 [23] J.S. Finlayson J.F. Mushinski Separation of subfractions of human β 2 -glycoprotein I Biochim Biophys Acta 147 1967 413 420 [24] X.D. Wang C.N. Zhang J.J. Wang Y. Tian Isolation and purification of apolipoprotein H with heparin affinity column self-prepared and its antibody preparation and identification Chin J Immun 24 2008 931 934 in Chinese [25] J.J. Albers W.R. Hazzard Immunochemical quantification of human plasma Lp(a) lipoprotein Lipids 9 1974 15 26 [26] M. Naruszewicze X. Girou J. Davignon Oxidative modification of Lp(a) causes in the structure and biological properties of apo(a) Chem Phys Lipids 67/68 1994 167 174 [27] J.J. Wang C.N. Zhang J.B. Gong Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody Clin Chim Acta 385 2007 73 78 [28] J.J. Wang Y.Y. Zhuang X.D. Yao Quantitation of plasminogen epitopes of serum lipoprotein(a) by sandwich enzyme linked immunosorbent assay Clin Chim Acta 265 1997 121 130 [29] G. Virella S.R. Thorpe N.L. Alderson Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies J Lipid Res 45 2004 1859 1867 [30] J. Frostegard Autoimmunity, oxidized LDL and cardiovascular disease Autoimmun Rev 1 2002 233 237 [31] J. Frostegard E. Svenungsson R. Wu Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations Arthritis Rheum 52 2005 192 200 [32] W.N. Huang T.K. Tso H.Y. Huang Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus Rheumatol Int 27 2007 453 458 [33] M. McMahona B.H. Hahna Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association Curr Opin Immunol 19 2007 633 669 [34] J.J. Wang B. Hu L.T. Kong H. Cai C.N. Zhang Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation Clin Chim Acta 390 2008 67 71 [35] F.I. Romero T. Atsumi F.J. Tinahones Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome Arthritis Rheum 43 2000 2141 2142 [36] K. Kobayashi M. Kishi T. Atsumi Circulating oxidized LDL forms complexes with β 2 -glycoprotein I: implication as an atherogenic autoantigen J Lipid Res 44 2003 716 726 [37] N. Bassi A. Ghirardello L. Iaccarino OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients Autoimmun Rev 7 2007 52 58